NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday an agreement with Pharma Mar to conduct BRCA1 and BRCA2 testing on patients enrolled in a clinical study for the drug firm's novel drug candidate.
Under the agreement, Myriad will conduct testing for patients in a Phase II clinical study for Pharma Mar's PM1183 drug candidate, which induces double-stranded DNA break to cause cell death. Myriad will evaluate BRCA status in patients who respond to the drug candidate.
Financial and other terms were not disclosed.
Myriad has similar deals with Abbott Pharmaceuticals, AstraZeneca, BioMarin Pharmaceuticals, and Cephalon to provide companion diagnostic testing with the BRACAnalysis test for clinical trial enrollment, it said.